BS_RSRPX3S8
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 60.480000000000004
- os_event
- false
- age_years
- 3.384
- sex
- F
- race
- White
- new_clusters
- S2
- umap1_2d
- -1.139625198
- umap2_2d
- -8.8448595
- umap1_3d
- -3.249852952
- umap2_3d
- -2.33603244
- umap3_3d
- 5.228977545
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.600
- MYC_TARGETS_V2+0.540
- OXIDATIVE_PHOSPHORYLATION+0.540
- E2F_TARGETS+0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.480
- INTERFERON_ALPHA_RESPONSE+0.470
- ALLOGRAFT_REJECTION+0.460
- INTERFERON_GAMMA_RESPONSE+0.430
- MTORC1_SIGNALING+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
Top 10 suppressed
- HEME_METABOLISM-0.110
- TGF_BETA_SIGNALING-0.080
- HEDGEHOG_SIGNALING-0.070
- ANGIOGENESIS-0.060
- KRAS_SIGNALING_DN-0.040
- MITOTIC_SPINDLE+0.020
- P53_PATHWAY+0.020
- TNFA_SIGNALING_VIA_NFKB+0.020
- SPERMATOGENESIS+0.040
- ESTROGEN_RESPONSE_EARLY+0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0368 | Med | Medulloblastoma | 0.946 |
| 2 | MDT-AP-1185 | Med | Medulloblastoma | 0.905 |
| 3 | MDT-AP-0428 | Med | Medulloblastoma | 0.891 |
| 4 | SRR13311163 | — | — | 0.888 |
| 5 | SRR1313147 | — | E | 0.887 |
| 6 | BS_996ZS2A4 | ATRT | — | 0.886 |
| 7 | MDT-AP-1144 | Med | Medulloblastoma | 0.884 |
| 8 | SRR8942975 | — | — | 0.876 |
| 9 | D06FFD0C-80D4-413D-9C83-62D9C163EDAB | — | — | 0.875 |
| 10 | SRR8942937 | — | — | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.540 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.480 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.350 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |